Geoffrey M. Lynn

2.8k total citations · 1 hit paper
18 papers, 782 citations indexed

About

Geoffrey M. Lynn is a scholar working on Immunology, Oncology and Biomedical Engineering. According to data from OpenAlex, Geoffrey M. Lynn has authored 18 papers receiving a total of 782 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology, 7 papers in Oncology and 5 papers in Biomedical Engineering. Recurrent topics in Geoffrey M. Lynn's work include Immunotherapy and Immune Responses (11 papers), CAR-T cell therapy research (4 papers) and Immune Cell Function and Interaction (4 papers). Geoffrey M. Lynn is often cited by papers focused on Immunotherapy and Immune Responses (11 papers), CAR-T cell therapy research (4 papers) and Immune Cell Function and Interaction (4 papers). Geoffrey M. Lynn collaborates with scholars based in United States, Czechia and United Kingdom. Geoffrey M. Lynn's co-authors include Getahun Merga, Dan Meisel, Robert L. Wilson, Bratoljub H. Milosavljevic, Andrew S. Ishizuka, Robert A. Seder, Faezzah Baharom, Ramiro A. Ramirez-Valdez, Gary G. Nicholas and James Reed and has published in prestigious journals such as Cell, Nature Communications and Nature Immunology.

In The Last Decade

Geoffrey M. Lynn

18 papers receiving 765 citations

Hit Papers

Systemic vaccination induces CD8+ T cells and remodels th... 2022 2026 2023 2024 2022 40 80 120

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Geoffrey M. Lynn United States 11 329 230 206 149 142 18 782
David T. Valenta United States 10 146 0.4× 298 1.3× 199 1.0× 145 1.0× 62 0.4× 14 876
Eiji Takahashi Japan 15 205 0.6× 162 0.7× 180 0.9× 46 0.3× 138 1.0× 57 950
Sándor Sávay United States 11 317 1.0× 392 1.7× 89 0.4× 180 1.2× 77 0.5× 14 1.2k
Zhiwei Yin China 15 144 0.4× 140 0.6× 59 0.3× 157 1.1× 108 0.8× 40 673
Marine Z. C. Hatit United States 16 142 0.4× 924 4.0× 79 0.4× 127 0.9× 42 0.3× 17 1.2k
Kelsey L. Swingle United States 19 287 0.9× 1.1k 4.8× 249 1.2× 248 1.7× 61 0.4× 24 1.5k
Consol Farrera Spain 12 460 1.4× 318 1.4× 51 0.2× 191 1.3× 294 2.1× 12 1.0k
Regina Tavano Italy 20 299 0.9× 440 1.9× 37 0.2× 194 1.3× 170 1.2× 40 1.2k

Countries citing papers authored by Geoffrey M. Lynn

Since Specialization
Citations

This map shows the geographic impact of Geoffrey M. Lynn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geoffrey M. Lynn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geoffrey M. Lynn more than expected).

Fields of papers citing papers by Geoffrey M. Lynn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geoffrey M. Lynn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geoffrey M. Lynn. The network helps show where Geoffrey M. Lynn may publish in the future.

Co-authorship network of co-authors of Geoffrey M. Lynn

This figure shows the co-authorship network connecting the top 25 collaborators of Geoffrey M. Lynn. A scholar is included among the top collaborators of Geoffrey M. Lynn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geoffrey M. Lynn. Geoffrey M. Lynn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Totsch, Stacie K., Andrew S. Ishizuka, Kyung‐Don Kang, et al.. (2024). Combination Immunotherapy with Vaccine and Oncolytic HSV Virotherapy Is Time Dependent. Molecular Cancer Therapeutics. 23(9). 1273–1281. 3 indexed citations
2.
Tihlaříková, Eva, Yaling Zhu, B. Porsch, et al.. (2024). Synthesis and Structure Optimization of Star Copolymers as Tunable Macromolecular Carriers for Minimal Immunogen Vaccine Delivery. Bioconjugate Chemistry. 35(8). 1218–1232. 3 indexed citations
3.
Finnigan, John P., Jenna H. Newman, Y. Patskovsky, et al.. (2024). Structural basis for self-discrimination by neoantigen-specific TCRs. Nature Communications. 15(1). 2140–2140. 7 indexed citations
4.
Wilson, David R., et al.. (2024). Structural optimization of diblock polymers that undergo thermo-responsive nanoparticle self-assembly for intravitreal drug delivery. European Polymer Journal. 212. 113054–113054. 6 indexed citations
5.
Ramirez-Valdez, Ramiro A., Faezzah Baharom, Ahad Khalilnezhad, et al.. (2023). Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression. Cell Reports. 42(6). 112599–112599. 16 indexed citations
6.
Baharom, Faezzah, Ramiro A. Ramirez-Valdez, Ahad Khalilnezhad, et al.. (2022). Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment. Cell. 185(23). 4317–4332.e15. 142 indexed citations breakdown →
7.
Babič, Michal, Marcela Filipová, Jiřina Hromádková, et al.. (2022). Polymer-colloidal systems as MRI-detectable nanocarriers for peptide vaccine delivery. European Polymer Journal. 181. 111704–111704. 2 indexed citations
8.
Lynn, Geoffrey M., Pablo A. Valdés, Andrew S. Ishizuka, et al.. (2021). Therapeutic cancer vaccines for pediatric malignancies: advances, challenges, and emerging technologies. Neuro-Oncology Advances. 3(1). vdab027–vdab027. 17 indexed citations
9.
Pechar, Michal, et al.. (2021). Cyclotriphosphazene-Based Star Copolymers as Structurally Tunable Nanocarriers with Programmable Biodegradability. Macromolecules. 54(7). 3139–3157. 15 indexed citations
10.
Baharom, Faezzah, Ramiro A. Ramirez-Valdez, Hidehiro Yamane, et al.. (2020). Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells. Nature Immunology. 22(1). 41–52. 157 indexed citations
11.
Francica, Joseph R., Richard Laga, Geoffrey M. Lynn, et al.. (2019). Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates. PLoS Biology. 17(6). e3000328–e3000328. 32 indexed citations
12.
Totsch, Stacie K., Charles Schlappi, Kyung‐Don Kang, et al.. (2019). Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance. Oncogene. 38(34). 6159–6171. 53 indexed citations
13.
Lynn, Geoffrey M., Richard Laga, & Christopher M. Jewell. (2019). Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines. Cancer Letters. 459. 192–203. 26 indexed citations
14.
Lynn, Geoffrey M., Petr Chytil, Joseph R. Francica, et al.. (2019). Impact of Polymer-TLR-7/8 Agonist (Adjuvant) Morphology on the Potency and Mechanism of CD8 T Cell Induction. Biomacromolecules. 20(2). 854–870. 34 indexed citations
15.
Blobel, Nicolas J., et al.. (2017). Antigenic competition affects the magnitude and breadth of CD8 T cell immunity following immunization with a nanoparticle neoantigen cancer vaccine. The Journal of Immunology. 198(Supplement_1). 73.20–73.20. 2 indexed citations
16.
Fairhurst, Rick M., et al.. (2016). Breaking the Mold: Partnering with the National Institutes of Health Intramural Research Program to Accelerate PhD Training. Trends in Immunology. 37(12). 813–815. 2 indexed citations
17.
Merga, Getahun, Robert L. Wilson, Geoffrey M. Lynn, Bratoljub H. Milosavljevic, & Dan Meisel. (2007). Redox Catalysis on “Naked” Silver Nanoparticles. The Journal of Physical Chemistry C. 111(33). 12220–12226. 167 indexed citations
18.
Lynn, Geoffrey M., et al.. (1992). Risk factors for stroke after coronary artery bypass. Journal of Thoracic and Cardiovascular Surgery. 104(6). 1518–1523. 98 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026